TrialClinical and experimental immunology1993

Activation of the immune system of cancer patients by continuous i.v. recombinant IL-2 (rIL-2) therapy is dependent on dose and schedule of rIL-2.

J W Gratama et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.